Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL

Cancer Gene Therapy

Volumn 9, Issue 2, 2002, Pages 164-172

  Voelkel Johnson, Christina ^a   King, Deanne Lea ^a   Norris, James Scott ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adenovirus; Apoptosis; Cancer; Doxorubicin; Prostate; TRAIL Apo2L

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; DOXORUBICIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; TRANSGENE; TUMOR CELL LINE;

ADENOVIRIDAE;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BLOTTING, WESTERN; CARRIER PROTEINS; CASPASES; CELL SURVIVAL; CYTOCHROME C GROUP; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENETIC VECTORS; HUMANS; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036167572     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700420     Document Type: Article

References (37)

1. Cancer Statistics 2001
2. Gene therapy for prostate cancer: Where are we now?
3. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
4. Identification and characterization of a new member of the TNF family that induces apoptosis
5. Safety and antitumor activity of recombinant soluble Apo2 ligand
6. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-over-expressing chemotherapy-resistant tumor cells
7. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
8. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)
9. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
10. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
11. Molecular determinants of response to TRAIL in killing of normal and cancer cells
12. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
13. Sensitization of human colon cancer cells to TRAIL-mediated apoptosis
14. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis
15. Pretreatment with paclitaxel enhances Apo-2 ligand tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels
16. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics
17. Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis
18. The potential of TRAIL for cancer chemotherapy
19. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis
20. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene
21. The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer
22. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system
23. Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters
24. Green fluorescent protein as a novel tool to measure apoptosis and necrosis
25. Anthracyclines and anthracenediones
26. Apoptosis signaling by death receptors
27. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells
28. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines
29. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative
30. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
31. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
32. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells
33. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death
34. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells
35. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis
36. Widely used prostate carcinoma cell lines share common origins